Pfizer has created a cure for COVID-19: how it works and when it goes on sale
Pfizer Launches Global Phase 2/3 EPIC-PEP Study of a New COVID-19 Oral Antiviral Drug for Post-Exposure Prophylaxis in Adults. the official website of a pharmaceutical company.
EPIC-PEP (Evaluation of COVID-19 Protease Inhibition in Postexposure Prophylaxis) is the third study launched as part of this global clinical research program.
The new study will evaluate a new protease inhibitor (PF-07321332, given at the same time as low-dose ritonavir) for disease prevention in adults living in the same household as someone with COVID-19.
PF-07321332 has been specifically designed for oral administration, so it can potentially be administered at the first sign of infection or exposure to SARS-CoV-2, without the need to hospitalize patients.
Pfizer Inc. today announced the start of a Phase 2/3 EPIC-PEP (Evaluation of COVID-19 Protease Inhibition in Post-Exposure Prophylaxis) study to evaluate the investigational new oral antiviral candidate PF-07321332 co-administered with low dose ritonavir to prevent COVID-19 infection. This Phase 2/3 trial is part of a global clinical research program and includes individuals at least 18 years of age living in the same home as someone with confirmed symptomatic SARS-CoV-2 infection.
“Given the ongoing impact of COVID-19 around the world, we believe that fighting the virus will require effective treatments for people who have contracted or been exposed to the virus, complementing the impact vaccines have had in suppressing infections. If successful, we believe this therapy can help stop the virus early — before it can replicate widely — potentially preventing symptomatic disease in those exposed and suppressing the onset of infection in others. ” said Mikael Dolsten, M.D., Ph.D., Chief Scientist and President of Pfizer's International Research, Development and Medicine Division. “With the continued emergence and development of SARS-CoV-2 variants and their enormous impact, we continue to work diligently to develop and explore new ways in which our experimental oral antiviral candidate can potentially reduce the impact of COVID-19 on not only the patient, but also on his neighbors and family members.
The EPIC-PEP Phase 2/3 Study is a randomized, double-blind, placebo-controlled study in up to 2660 healthy adults aged 18 years and older. Participants will be randomly assigned (1: 1: 1) to receive PF-07321332 / ritonavir or placebo twice daily for 5 or 10 days. The main goal is to assess the safety and efficacy of preventing confirmed SARS-CoV-2 infection and its symptoms by day 14. PF-07321332 is an oral antiviral SARS-CoV-2-3CL protease inhibitor with promising preclinical results. Results from a Phase 1 clinical trial showed PF-07321332 to be safe and well tolerated.
In addition to this study, the global EPIC program consists of several ongoing clinical trials, including one involving patients infected with SARS-CoV-2 who are at high risk of severe illness (including hospitalization or death), which began in July 2021. and with the presence of other infected patients who are at standard risk (i.e., do not have risk factors for severe illness), which began in August 2021.
PF-07321332 is an investigational SARS-CoV-2-3CL protease inhibitor antiviral therapy specifically designed for oral administration so that it can be prescribed at the first sign of infection or at first awareness of exposure without requiring hospitalization of patients. Protease inhibitors such as PF-07321332 are designed to block the activity of the main protease enzyme that the coronavirus needs to replicate. Co-administration with a low dose of ritonavir is expected to help slow the metabolism or breakdown of PF-07321332 so that it remains active in the body for longer periods of time at higher concentrations to help fight the virus.
In March 2021, Pfizer introduced PF-07321332 in a Phase 1 study in healthy adults to evaluate the safety, tolerability and pharmacokinetics of the study compound. In July, he transitioned to a Phase 2/3 study, EPIC-HR (Evaluation of COVID-19 Protease Inhibition in High-Risk Patients), to evaluate the efficacy and safety in combination with ritonavir in participants with a confirmed diagnosis of SARS-CoV-2 infection with high risk of progression to severe illness.
In August, Pfizer began a Phase 2/3 study, EPIC-SR (Evaluation of COVID-19 Protease Inhibition in Patients at Standard Risk), to assess efficacy and safety in participants with a confirmed diagnosis of SARS-CoV-2 infection who are at standard risk. (i.e., do not have risk factors for severe illness).
You may be interested in: top New York news, stories of our immigrants and helpful tips about life in the Big Apple - read it all on ForumDaily New York.
PF-07321332 is the first investigational protease inhibitor specific for oral administration against coronavirus to be evaluated in clinical trials.
There is currently no approved oral therapy for post-exposure or preventive treatment for COVID-19.
Read also on ForumDaily:
stdClass Object ([term_id] => 1 [name] => Miscellaneous [taxonomy] => category [slug] => no_theme)Miscellaneous
stdClass Object ([term_id] => 12 [name] => In the US [taxonomy] => category [slug] => novosti-ssha)In the U.S.
stdClass Object ([term_id] => 10255 [name] => Pfizer [taxonomy] => post_tag [slug] => pfizer)Pfizer
stdClass Object ([term_id] => 28340 [name] => coronavirus [taxonomy] => post_tag [slug] => koronavirus)coronavirus
stdClass Object ([term_id] => 28353 [name] => READ ABOUT CORONAVIRUS [taxonomy] => special [slug] => kitajskij-koronavirus)
stdClass Object ([term_id] => 28455 [name] => COVID-19 [taxonomy] => post_tag [slug] => covid-19)COVID-19
stdClass Object ([term_id] => 29215 [name] => efficiency from COVID-19 [taxonomy] => post_tag [slug] => effektivnost-ot-covid-19)effectiveness against COVID-19
stdClass Object ([term_id] => 29318 [name] => third stage of drug research [taxonomy] => post_tag [slug] => tretya-stadiya-issledovaniya-lekarstva)third stage of drug research
Let's face the crisis together and support each other
Thank you for staying with us and trusting! Over the past 5 years, we have received a lot of grateful feedback from readers, whom our materials have helped to arrange life after moving to the United States. We have big plans, we do not want to stop or slow down the pace of work. Even now…
The COVID-19 pandemic has negatively affected our income, and in order to stay afloat, we have to ask YOU for support. We will be grateful for any amount and will make every effort to continue to publish news and a lot of useful information just as quickly.
Thank you for being with us!
Always yours, ForumDaily!
Security of contributions is guaranteed by the use of the highly secure Stripe system.
Do you want more important and interesting news about life in the USA and immigration to America? Subscribe to our page in Facebook. Choose the "Display Priority" option and read us first. Also, don't forget to subscribe to our РєР ° РЅР ° Р »РІ Telegram - there are many interesting things. And join thousands of readers ForumDaily Woman и ForumDaily New York - there you will find a lot of interesting and positive information.